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Abstract
The metastasis suppressor, BRMS1, has been
demonstrated to cause dramatic regression of
metastatic lesions without blocking orthotopic tumor
growth. The role of BRMS1 is well-documented for
several non-melanoma malignancies, such as breast
cancer, ovarian cancer and non-small-cell lung cancer.
However, its role in melanoma is just beginning to be
understood, with a recent article by Slipicevic et al.
highlighting the levels of expression of BRMS1 in
benign nevi, primary and metastatic melanoma
samples. Their findings emphasize that the
intracellular location of BRMS1 protein (cytoplasmic or
nuclear), appears to have a significant impact upon
the metastatic capacity of melanoma cells.
Interestingly, this selective localization translates into a
statistically significant decrease in the relapse-free
period in melanoma patients, further associated with
a thicker Breslow’s depth of primary melanomas.
However, and more importantly, this study begins to
define a clearer role for BRMS1 in melanoma that is
strictly dependent upon its cellular location, with
nuclear expression associated with invasive and
metastatic capacity and cytoplasmic expression
resulting in repressive effects upon progression and
metastasis.
Please see related article: http://www.biomedcentral.
com/1471-2407/12/73
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Background
It has been over a decade since the initial reports of the
discovery and functional relevance of Breast Cancer
Metastasis Suppressor 1 (BRMS1) [1,2]. Though the
initial reports stemmed from research performed on
breast cancer, convincing independent studies on sup-
pression of melanoma metastasis by BRMS1 were
described very early [3]. However, as the molecular
complexity of mechanisms of action of BRMS1 became
evident through several elegant studies [4-11], defining
the exact physiological and clinical context of these
activities remains elusive. Lastly, the central question
remains: Does the loss of BRMS1 expression result in
disease progression?
One well-described scenario may entail the loss of
BMRS1 expression in tumor tissue secondary to epige-
netic silencing [12,13]. Other possibilities include
changes in expression related to BRMS1 regulation at
the transcriptional and post-translational level, further
complicated by potential changes in overall protein sta-
bility. In a recent study published in BMC Cancer by
Slipicevic et al., the authors show that the intracellular
location of BRMS1, whether cytoplasmic or nuclear,
appears to affect relevant outcome parameters in mela-
noma patients.
Understanding why location is important
It is well known that the intracellular location and tim-
ing of protein expression could manifest as diverse bio-
logical activities. For example, the tumor suppressor
gene, P53, has been reported to be actively expressed in
the cytoplasmic, mitochondrial, nuclear and nucleolar
regions of tumor cells [14,15], with distinct activities
dependent upon its localization. BRMS1 is mainly con-
sidered to be a nuclear transcription co-repressor, due
to the presence of definitive nuclear localization signals
and reports of its participation in the chromatin remo-
deling complex(es). Interestingly, BRMS1 has a func-
tional nuclear export signal indicating its capability to
shuttle through cellular compartments [16] (Figure 1).
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partment are still to be defined. Slipicevic et al. also
show that nuclear presence of BRMS1 in melanoma cor-
relates with fatty acid binding protein 7 (FABP7). This
study implies a possible role of nuclear BRMS1 as a pro-
moter of invasion, further supported by silencing of
BRMS1. Further relevant data may be obtained through
distinct experiments that target BRMS1 function to dis-
tinct compartments, revealing more mechanistic details.
It will also be interesting if FABP7 is found to be a
downstream target of nuclear BRMS1.
Does it really matter where BRMS1 expression is found?
This paper has consistently shown that there are signifi-
cant differences in staining intensity between cytoplas-
mic and nuclear BRMS1 expression. Ultimately, the
question can be asked as to whether the specific loca-
tion of BRMS1 activity can make a difference in the des-
tined outcome for melanoma patients. The work shows
that high intensity cytoplasmic staining for BRMS1
expression is associated with a significantly higher
relapse-free period compared to lower staining cells.
Conversely, intense nuclear staining is associated with a
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Figure 1 Location(s) of BRMS1 and corresponding activities. BRMS1 is a transcription co-repressor and can shuttle between nucleus and
cytoplasm. BRMS1 levels are governed by ubiquitin-mediated degradation. In the nucleus, it shows inhibition of some transcripts and up-
regulation others. However, some of these regulations may be due to its cytoplasmic activities (such as deacetylation of NFB members). The
ultimate impact of BRMS1 on a specific tumor cell appears to be tumor type and context-dependent. Abbreviations: BRMS1, breast cancer
metastasis suppressor-1; FABP7, fatty acid binding protein-7; ING-4, inhibitor of growth family, member-4; Cul3, Cullin-3; SPOP, speckle-type POZ
domain protein; mSin3, mammalian Sin3; HDAC, histone deacetylase; Cx32, 43, connexin-32, -43; uPA, urokinase-type plasminogen activator; OPN,
osteopontin; miR, micro ribonucleic acid; Nexin6, sorting nexin-6.
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cells within the nucleus of melanoma cells.
Ultimately, does it really matter where BRMS1 is
being expressed to the patient or clinician? Is there any-
thing that can be done to change the ultimate outcome
for these patients? Can one utilize this ratio of BRMS1
staining information as a potential prognostic marker
for such patients? BRMS1 can have multiple spliced var-
iants [17]; thus, is the location specific to any of these
s p l i c ev a r i a n t s ?C a nw ec h a n g et h eb a l a n c ei nf a v o ro f
higher expressing cytoplasmic BRMS1 expression, with
concomitant lower nuclear levels? What are the details
of interactions between FABP7, activated ERK1/2 and
Akt within the nucleus? A recent study has shown that
the cell cycle regulator, ING4, is a suppressor of mela-
noma angiogenesis, regulated and induced by BRMS1
expression and further inhibiting NF-KB activity and IL-
6 expression [18]. Thus, many other questions emerge
unanswered and will require further research to eluci-
date the importance of BRMS1 expression in melanoma,
whether nuclear or cytoplasmic.
Recent evidence strongly suggests that BRMS1 repre-
sents an important biomarker with prognostic signifi-
cance, further serving as a therapeutic target for
melanoma patients [19]. Other correlations and possible
biomarkers have also been identified, such as an inverse
relationship with osteopontin levels in melanoma cells
and tumor specimens [13]. Looking forward, if one was
capable of restoring BRMS1 expression via reversal of
epigenetic silencing, could we concomitantly regulate its
intracellular location and activity in tumor cells to
achieve the desired therapeutic outcome in melanoma
patients.
Conclusion
Slipicevic et al. show for the first time that there is a
differential expression of BRMS1 within the cytoplasm
and nucleus of melanoma cells, with cellular localization
determining its effect within the tumor microenviron-
ment. Such differences are associated with a significant
difference in the relapse-free period, with cytoplasmic
BRMS1 expression restricting melanoma progression
and nuclear expression likely associated with cell inva-
sion. From a treatment perspective, the importance of
this study will be realized if bioactive agents can be
developed that have the capacity to change both the
(natural) balance and location of BRMS1 expression
within melanoma cells.
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